Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.
We utilise both egg and cell-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies whilst working on longer-term transformational approaches to influenza protection.
As part of the CSL Group, we have been producing influenza vaccine in Melbourne, Australia since the 1940’s. Our site in Liverpool UK, is a Centre of Excellence for adjuvanted influenza vaccine manufacturing while our state-of-the-art production facility in Holly Springs US, was purpose-built to harness newer cell-based technology.
|
|
|
201-500 employees
View all Seqirus employees
|
|
Pharmaceuticals
|
|
None
|
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.